In the BioHarmony Drug Report Database

"Preview" Icon

Paritaprevir

Technivie, Viekirax (paritaprevir) is a small molecule pharmaceutical. Paritaprevir was first approved as Technivie on 2015-01-14. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Viekira pak’s patents are valid until 2032-04-13 (FDA).

 

Trade Name

 

Viekirax
 

Common Name

 

paritaprevir
 

ChEMBL ID

 

CHEMBL3391662
 

Indication

 

chronic hepatitis c, hepatitis c
 

Drug Class

 

Antivirals: serine protease inhibitors

Image (chem structure or protein)

Paritaprevir structure rendering